Financial Survey: IDEAYA Biosciences (NASDAQ:IDYA) vs. Gossamer Bio (NASDAQ:GOSS)

IDEAYA Biosciences (NASDAQ:IDYA) and Gossamer Bio (NASDAQ:GOSS) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for IDEAYA Biosciences and Gossamer Bio, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1	1	13	0	2.80
Gossamer Bio	2	3	5	0	2.30

IDEAYA Biosciences presently has a consensus target price of $51.09, indicating a potential upside of 52.51%. Gossamer Bio has a consensus target price of $256.00, indicating a potential upside of 2,520.27%. Given Gossamer Bio’s higher possible upside, analysts clearly believe Gossamer Bio is more favorable than IDEAYA Biosciences.

Institutional & Insider Ownership

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by insiders. Comparatively, 4.2% of Gossamer Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares IDEAYA Biosciences and Gossamer Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	N/A	N/A
Gossamer Bio	N/A	N/A	N/A

Valuation & Earnings

This table compares IDEAYA Biosciences and Gossamer Bio”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	N/A	N/A	N/A	($1.94)	-17.27
Gossamer Bio	N/A	N/A	N/A	($56.00)	-0.17

IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Summary

IDEAYA Biosciences beats Gossamer Bio on 5 of the 6 factors compared between the two stocks.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

About Gossamer Bio

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.